AI-driven platform developing rapid, novel therapies for rare and inflammatory diseases.
GEn1E Lifesciences, founded with the mission to accelerate the development of therapies for rare and inflammatory diseases, leverages an advanced AI platform to create novel immunomodulatory treatments. The company focuses on addressing diseases with no effective treatments by applying AI to multiple-mechanism-of-action protein targets. Their core product offerings include precision therapies developed at an unprecedented pace, with a notable focus on conditions such as Acute Respiratory Distress Syndrome (ARDS).
Key figures affiliated with GEn1E Lifesciences include experts in AI and drug development, though specific names are not provided. The company's AI platform, GRID™, has been instrumental in discovering new binding pockets and validating unique mechanisms of action, contributing to significant advancements in the field. GEn1E's impact is marked by its potential to unlock billion-dollar opportunities in the pharmaceutical industry, positioning it as a transformative player in the development of first-in-class therapies for complex diseases.

1910 Genetics
1910genetics.com

Genesis Therapeutics

Generate Biomedicines

Synkrino Biotherapeutics

Ordaos
ordaos.bio

Arpeggio Bio
arpeggiobio.com

Output Biosciences
outputbio.com

Probably Genetic

WhiteLab Genomics
whitelabgx.com

Diffuse Bio
diffuse.bio

Emedgene
emedgene.com

Endpoint Health
endpointhealth.com

OneThree Biotech
onethree.bio

Algen Biotechnologies
algenbio.com

Genemod
genemod.net
Companies similar to GEn1E Lifesciences include 1910 Genetics, Genesis Therapeutics, Generate Biomedicines and Synkrino Biotherapeutics.
GEn1E Lifesciences was founded in 2018.
GEn1E Lifesciences' headquarters is located in Palo Alto, CA, US.
GEn1E Lifesciences' most recent funding round was for $17M (USD) in December 2022.
As of Dec 21, 2022, GEn1E Lifesciences has raised a total of $17M (USD).
GEn1E Lifesciences has 16 employees as of Feb 5, 2024.